Stock Market Reviews

COYA (Coya Therapeutics, Inc.) News

Get the latest news, insights, and market updates on COYA (Coya Therapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Coya Therapeutics (COYA) Valuation in Focus After Follow-On Equity Offering Announced
  Coya Therapeutics (COYA) caught investors' attention after announcing a follow-on equity offering of its common stock. Equity offerings like this often prompt questions about a company's capital needs and long-term growth strategy. See our latest analysis for Coya Therapeutics. Following the announcement of its follow-on equity offering, Coya Therapeutics has seen its share price surge 32.95% over the past month as investors respond to the potential for renewed growth and improved financial...
  Oct 24, 2025 - $COYA
• Investors Digest September Inflation Report, Lifting US Equity Futures Pre-Bell
  US equity futures were up ahead of Friday's opening bell as traders digested a key inflation metric
  Oct 24, 2025 - $COYA
• Coya Therapeutics Announces Proposed Public Offering of Common Stock
  HOUSTON, October 23, 2025--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The Company also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common
  Oct 23, 2025 - $COYA
• Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function
  HOUSTON, October 07, 2025--Coya Therapeutics, Inc. (NASDAQ: COYA) congratulates our long-standing scientific advisor, Dr. Shimon Sakaguchi, on being awarded the Nobel Prize for his pioneering discovery of regulatory T cells (Tregs) which protect the body from autoimmune diseases. This discovery has reshaped modern immunology and opened new therapeutic frontiers.
  Oct 7, 2025 - $COYA
• Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia
  Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces completion of patient enrollment of an investigator-initiated, proof-of-concept, open-label study with low-dose IL-2 and CTLA4-Ig combination treatment in patients with Frontotemporal Dementia (FTD). The study is led by Dr. Alireza Faridar and Dr. Stanley Appe
  Sep 29, 2025 - $COYA
• Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis
  Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced today the launch of the ALSTARS Trial, a Phase 2, randomized, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of COYA 302 for the treatment of ALS (ClinicalTrials.gov Identifier: NCT 07161999).
  Sep 22, 2025 - $COYA
• Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model
  Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, today announced results of a study designed to evaluate the effects of COYA 303 (LD IL-2 and GLP-1RA), Coya's investigational biologic combination in an established in vivo lipopolysaccharide (LPS) mouse model of systemic and neuroinflammation. Results from the first animal cohort treated with COYA 303 demonstrated br
  Sep 16, 2025 - $COYA
• EXCLUSIVE: Coya Therapeutics Investigational Combination Therapy With GLP-1 Shows Potential For Alzheimer's Disease
  Coya Therapeutics Inc. (NASDAQ:COYA) on Tuesday announced results from a study designed to evaluate the effects of COYA 303 (LD IL-2 and GLP-1RA), Coya's investigational biologic combination, in an in vivo lipopolysaccharide (LPS) mouse model of systemic and neuroinflammation. Results from the first animal cohort treated with COYA 303 demonstrated broad systemic and central immunomodulatory activity, including significant reductions in LPS-induced pro-inflammatory myeloid cells and associated cy
  Sep 16, 2025 - $COYA
• Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial
  Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, today announced that its upcoming Phase 2 clinical trial to evaluate the efficacy and safety of COYA 302 in patients with ALS has been accepted as a NEALS-Affiliated Trial by the NEALS Consortium.
  Sep 4, 2025 - $COYA
• PRISM MarketView Features Exclusive Q&A with Coya Therapeutics CEO Arun Swaminathan on Targeting Neurodegenerative Diseases Through Treg Therapies
  Q&A Highlights FDA IND Clearance, Partnerships, and 2025 Milestones Across ALS and Neurodegeneration ProgramsNEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PRISM MarketView today published a Q&A feature with Arun Swaminathan, Chief Executive Officer of Coya Therapeutics, Inc. (“Coya” or the “Company”) (NASDAQ: COYA), a clinical-stage biotechnology company developing Treg-modulating therapies to address ALS and other neurodegenerative diseases.Arun Swaminathan, CEO, Coya Therapeutics, Inc.In the in
  Sep 3, 2025 - $COYA